Compare · ATLN vs BIO
ATLN vs BIO
Side-by-side comparison of Atlantic International Corp. (ATLN) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATLN and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $7.80B, about 132.4x ATLN ($58.9M).
- Over the past year, ATLN is down 68.6% and BIO is up 29.0% - BIO leads by 97.6 points.
- ATLN has hit the wire 3 times in the past 4 weeks while BIO has been quiet.
- BIO has more recent analyst coverage (12 ratings vs 0 for ATLN).
- Company
- Atlantic International Corp.
- Bio-Rad Laboratories Inc.
- Price
- $0.75-18.32%
- $291.34-0.99%
- Market cap
- $58.9M
- $7.80B
- 1M return
- -49.64%
- +13.28%
- 1Y return
- -68.55%
- +29.01%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- 1980
- News (4w)
- 3
- 0
- Recent ratings
- 0
- 12
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest ATLN
- Atlantic International Corp Receives Notification from Nasdaq Regarding Late Filing of Form 10-Q
- SEC Form 424B3 filed by Atlantic International Corp.
- SEC Form NT 10-Q filed by Atlantic International Corp.
- SEC Form RW filed by Atlantic International Corp.
- Atlantic International's Circle8 Group Secures $380 Million Four-Year Technology Services Contract with Dutch Ministry of Education, Culture, and Science
- Atlantic International's Circle8 Recognized as One of the Fastest-Growing IT and Technology Solutions Platforms in the Netherlands
- Atlantic International Expands its $1.2 Billion Revenue (Unaudited) Platform into AI, Cybersecurity, and Data Infrastructure Through Circle8
- Atlantic International Reports Fourth Quarter and Full Year 2025 Results
- SEC Form 10-K filed by Atlantic International Corp.
- SEC Form 424B3 filed by Atlantic International Corp.
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025